Tesla's sales decline in Europe continues despite new lower-cost models, while industry buzz swirls around a hotly denied report of potential Ford-Xiaomi collaboration. Meanwhile, U.S. dealers show surprising pragmatism toward the EV transition.
Despite a modest price target reduction, Morgan Stanley reaffirms its Overweight rating on Wingstop, citing the chicken wing chain's robust unit expansion and system-wide sales momentum as key drivers for its 2026 outlook.
With the FIFA World Cup in North America, the Milano Cortina Winter Olympics, and a packed calendar of major events, 2026 is poised to be a landmark year for sports. Brands and retailers are deploying sophisticated strategies that prioritize cultural marketing and community engagement over mere sales spikes, navigating a landscape where consumer loyalty is won through storytelling, not just sponsorship.
Piper Sandler raises its price target on ImmunityBio, citing a near 700% surge in Anktiva sales and promising interim data from the QUILT trials that could support a major label expansion by 2027.
With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.
Footwear giant Deckers Brands announced a 7.1% rise in Q3 FY26 net sales to $1.95 billion, driven by explosive growth from its HOKA running brand and solid gains from UGG, despite a challenging retail environment.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
Pharmaceutical giant Eli Lilly enters a strategic collaboration potentially worth up to $1.93 billion with biotech firm Repertoire Immune Medicines, aiming to develop precision treatments for autoimmune diseases that move beyond broad immunosuppression.
Seaport Research analyst Scott Graham lowered Badger Meter's price target to $220 from $255, citing a slower sales pace in early 2025. The firm maintains a Buy rating, anticipating a stronger second half. The water technology company recently reported record annual sales and profits.
The Ermenegildo Zegna Group reported a 1.1% organic revenue increase to €1.91 billion for 2025, powered by robust DTC performance. While annual sales dipped slightly on a reported basis, a strong fourth-quarter acceleration signals the payoff of its strategic channel shift.
While EyePoint Pharmaceuticals (EYPT) shares have retreated 23% this month, long-term shareholders are still sitting on massive gains. The biotech's 195% three-year surge, despite ongoing losses, highlights a classic market puzzle: balancing current financials with future potential.
The spirits giant files for legal protection for its production and warehouse assets in Latvia, citing cash flow pressures from geopolitical fallout and market headwinds, while assuring global sales remain unaffected.
Despite underperforming the broader market since August 2025, insurance marketplace platform MediaAlpha (MAX) exhibits robust fundamentals—including sustained sales growth, expanding cash flow margins, and rising returns on capital—that could signal significant upside potential for patient investors.
While robust cash generation is a hallmark of financial health, it doesn't guarantee stock outperformance. We examine three companies—PVH, Scorpio Tankers, and Amneal Pharmaceuticals—where strong cash flows are overshadowed by strategic challenges, raising red flags for discerning investors.
Mazda Motor Corporation's global vehicle production saw a significant rebound in December 2025, offering a positive end to a year where overall output and sales declined. The recovery was driven by strong domestic performance and a mixed picture overseas.
The UK pharmaceutical giant AstraZeneca begins trading ordinary shares on the New York Stock Exchange today, a significant upgrade from its previous Nasdaq ADR listing. This move underscores the company's strategic rebalancing towards the United States, its largest market, and raises questions about the long-term relevance of its London listing.
Graco Inc. delivered solid fourth-quarter results, meeting analyst forecasts with 8% sales growth driven by acquisitions and stable core demand. While management expressed confidence in integration efforts and margin initiatives, analysts on the earnings call pressed for details on long-term profitability and market headwinds.
The iconic pottery maker reports encouraging sales growth and a renewed focus on its craft heritage, aiming to return to profitability next year after a period of job cuts and industry-wide challenges.
While the UK kitchenware retailer maintains sales growth, a five-year decline in a key profitability metric and rising liabilities signal potential headwinds for investors.
Takeda Pharmaceutical's (TSE:4502) recent share price rally has ignited a debate among investors. With the stock closing at ¥5,242, analysts are divided on its true worth, presenting a complex picture of fair value signals and future growth prospects.
